Article3 Biotech2025
Potentials of cepharanthine and tomatidine as novel LpxC and TLR4 inhibitors to mitigate gut-mediated inflammation in Parkinson's disease: a high-throughput investigation through molecular docking and dynamic simulation.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut dysbiosis is strongly implicated in the pathogenesis of Parkinson's disease (PD), where the interaction between bacterial endotoxin lipopolysaccharide (LPS) and human toll-like receptor 4 (TLR4) plays a crucial role. Inhibiting LPS-synthesizing enzyme LpxC and LPS-TLR4 interaction will reduce bacterial load and gut-brain inflammation. Side effects associated with the currently investigated synthetic inhibitors urge the need for effective alternatives. The present study was conducted to identify LpxC and TLR4 inhibitors from phyto-alkaloids, a class well-known for its therapeutic abilities. 505 alkaloids were yielded from the database search, amongst which 314 alkaloids showed gut-blood and blood-brain barrier permeability, and favorable drug-likeness. Site-specific docking of 314 alkaloids yielded 29 and 88 hit ligands for LpxC and TLR4 respectively. Subsequently, the molecular interaction analysis revealed cepharanthine as the most potential dual inhibitor of LpxC and TLR4, followed by tomatidine. Greater affinity, strength, and stability observed in molecular dynamic simulation further strengthened the LpxC and TLR4 inhibition by cepharanthine and tomatidine, with cepharanthine being a more potential TLR4 inhibitor and tomatidine a better LpxC inhibitor. Pharmacokinetic property assessment suggested favorable absorption, distribution, metabolism, and elimination of tomatidine, while the clinical application of cepharanthine for snake bite, leukopenia, and alopecia supports its minimal toxicity. Presenting cepharanthine and tomatidine as dual inhibitors of LpxC and TLR4, the study suggests a plausible multitarget single or combinatorial drug therapy strategy for countering gut dysbiosis and PD. However, preclinical and clinical investigations and improved pharmacokinetics of cepharanthine and tomatidine are warranted to validate our in silico findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.